Your Health, We Care
Hormone Receptor-Positive, HER2-Negative Breast Cancer: Indicated for postmenopausal women in combination with exemestane for the treatment of advanced patients whose disease has progressed following letrozole or anastrozole therapy.
Neuroendocrine Tumors (NETs):
Indicated for adults with progressive pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic.
Indicated for adults with progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or pulmonary origin that are unresectable, locally advanced, or metastatic.
Usage Restriction: Not indicated for the treatment of functional carcinoid tumors.
Renal Cell Carcinoma (RCC): Indicated for adults with advanced renal cell carcinoma following failure of sunitinib or sorafenib therapy.
TSC-Associated Renal Angiomyolipoma: Indicated for adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) who do not require immediate surgery.
TSC-Associated Subependymal Giant Cell Astrocytoma (SEGA): Indicated for adults and pediatric patients aged 1 year and older with tuberous sclerosis complex (TSC) for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected surgically.
TSC-Associated Partial Seizures: Indicated for adults and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC) as adjunctive therapy for partial seizures.
FDA，2022.02
